



Universiteit
Leiden
The Netherlands

Hemostatic risk factors and arterial thrombotic disease

Rosendaal, F.R.

Citation

Rosendaal, F. R. (2001). Hemostatic risk factors and arterial thrombotic disease, 584-595.
Retrieved from <https://hdl.handle.net/1887/1627>

Version: Not Applicable (or Unknown)

License:

Downloaded from: <https://hdl.handle.net/1887/1627>

Note: To cite this publication please use the final published version (if applicable).

Review Articles

Hemostatic Risk Factors and Arterial Thrombotic Disease

Alexander P. Reiner¹, David S. Siscovick¹, Frits R. Rosendaal²¹Cardiovascular Health Research Unit, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA; ²The Hemostasis and Thrombosis Research Center and Department of Clinical Epidemiology, University Hospital Leiden, The Netherlands

The pathogenesis of arterial thrombotic disease involves multiple genetic and environmental factors related to atherosclerosis and thrombosis. Acute thrombosis at the site of a ruptured, lipid-rich atherosclerotic plaque is the usual precipitating event in the transition from stable or subclinical atherosclerotic disease to acute myocardial infarction (MI), stroke, or peripheral arterial occlusion (1). Pathologic studies of coronary arteries in acute MI suggest that the acute thrombosis likely involves activation of both platelets and the coagulation system.

Following atherosclerotic plaque rupture, platelets initially adhere to exposed subendothelial von Willebrand factor (vWF) and collagen through the glycoprotein Ib/IX receptor complex and the glycoprotein Ia/IIa receptor complex, respectively. The attachment of platelets to the vascular subendothelium (platelet adhesion) induces a series of intracellular signaling events that result in platelet activation. The binding of fibrinogen and vWF to the conformationally active form of the glycoprotein IIb/IIIa receptor results in platelet cohesion or aggregation, and further propagation of the platelet thrombus. Plaque rupture also results in exposure of subendothelial tissue factor, which initiates the coagulation cascade, and leads to the generation of thrombin and formation of a fibrin clot. While arterial thrombi traditionally are considered to be composed predominantly of platelets, accumulating evidence suggests that certain arterial thrombotic disorders (e.g., transmural or "Q-wave" MI) are associated with greater activation of the coagulation system, which results in occlusive thrombi that are relatively rich in fibrin (2).

Prevention of arterial thrombotic diseases, such as myocardial infarction and ischemic stroke, has focused on identification and modification of traditional cardiovascular risk factors, such as smoking, hyperlipidemia, hypertension, and obesity, that are related to atherosclerosis. However, approximately 30% of MI occur in individuals without traditional cardiovascular risk factors (3). Since antithrombotic agents such as aspirin have been shown to be beneficial in primary and secondary prevention of arterial thrombosis (4), attention has shifted in recent years to the characterization and evaluation of novel phenotypic markers of cardiovascular disease, involving lipoprotein metabolism, the coagulation and fibrinolytic systems, and inflammation (5, 6). In addition, the identification of molecular variants within the genes encoding proteins involved in the pathogenesis of thrombosis has led to their evaluation as genetic susceptibility markers in epidemiologic studies of arterial thrombotic disease. In this review, we briefly discuss some general issues related to the studies that examine the associations

of both genetic susceptibility markers and intermediate hemostatic phenotypes with arterial thrombotic disease. We then review the evidence pertaining to the role of specific genetic markers and hemostatic phenotypes in arterial thrombosis.

General Issues Related to Study Design and Interpretation of Results

Case-control and cross-sectional studies assess the relationship between phenotypic markers (e.g., plasma coagulation factor levels) and the occurrence of arterial thrombotic disease. However, these studies cannot establish a temporal order, and therefore cannot exclude the possibility that a hemostatic phenotype is a consequence of the disorder (e.g., due to accompanying tissue injury or inflammation). Even in prospective cohort studies, the observed associations may be confounded by subclinical atherosclerosis, which may contribute to both the hemostatic phenotypes as well as the clinical outcomes. In addition, plasma levels of hemostatic factors are sometimes correlated with each other and also are influenced by other cardiovascular risk factors (e.g., obesity, hyperlipidemia, smoking), that may further confound an apparent relationship between the hemostatic marker and risk of disease. For these reasons, the most convincing evidence of a causal relationship between a hemostatic phenotype and the occurrence of arterial thrombotic disease is inferred from clinical trials that demonstrate that altering the phenotype (e.g., lowering plasma levels of the hemostatic factor) reduces disease.

Another means of circumventing some of the spurious conclusions that can result from the use of intermediate hemostatic phenotypes is to analyze genetic variants that are known to be related to phenotypic variation. The advantage of studying genetic variants is that they are "fixed at birth", and therefore clearly precede disease onset and are not confounded by other behavioral and environmental cardiovascular risk factors or subclinical atherosclerosis. However, molecular epidemiologic studies evaluating potential genetic susceptibility markers have their own set of limitations, and different studies evaluating the same genetic marker often yield conflicting results. Comparison of results among studies is hampered by differences in study design and characteristics of case patients and control subjects, variation of allele frequencies among different populations, as well as the complexity and heterogeneity of the clinical endpoints of coronary heart disease, stroke, and peripheral arterial occlusion. These complex disorders likely involve the effects of multiple genes interacting with the environment. The effect of any single genetic susceptibility factor alone for arterial thrombotic disease is likely to be modest, but may assume greater importance in the presence of additional genetic or environmental exposures (i.e., gene-gene or gene-environment interaction). The

Correspondence to: Alexander P. Reiner, M.D., Harborview Medical Center, 325 9th Avenue, Box 359756, Seattle, Washington 98104, USA - Tel.: +1206-731-3291; Fax: +1206-341-5312; E-mail: apreiner@u.washington.edu

associ-
nal th
popul.
strate
expos
Alt
ronme
to con
stratifi
of the
both v.
case in
by spec
Anothe
not in
volved
with th
gene na
non tra
mutatio
able to
to the 1
tribute s

Coagu

Fibrino

Plasm
associat
studies o
athero-th
in the hig
the lowe
disease v
tion, plas
and smoo
acute pha
C-reactivi
jects that
tribute to
also high
age, smok
possesses
not associ
a recent cl
Human
β and γ.
in vitro, th
and severa
individual
union with
matched mo
the populat
those with
αA β-fibr
antroversi.
(15-17), an
consistent
ship between

association between a putative genetic susceptibility marker and arterial thrombotic disease may only be demonstrable within a certain sub-population. As a result, large sample sizes may be required to demonstrate a statistically stable estimate of effect, particularly for alleles or polymorphic subgroups that are uncommon within the population.

Although not subject to confounding by other behavioral and environmental risk factors, population studies of genetic variants are subject to confounding by ethnicity, i.e., population admixture or "population stratification". Thus, a spurious association may arise if the frequency of the genetic marker and the frequency of arterial thrombotic disease vary according to genetic ancestry. This is most likely to be the case in ethnically heterogeneous populations, and can be accounted for in specific analyses that assess genetic linkage as well as association. Another possible reason for a positive association in some studies but not in others is that the genetic marker of interest is not directly involved in disease susceptibility, but rather is in linkage disequilibrium with the actual causative mutation located in the same gene or another gene nearby. Depending on the population history and the recombination fraction, the genetic marker may be associated with the causative mutation in some populations but not in others. Therefore, it is preferable to assess genetic markers that are well-characterized with respect to the functional consequences of the molecular defect and that contribute significantly to phenotypic variation within the population.

Regulation Factors

Fibrinogen

Plasma fibrinogen levels have been consistently and independently associated with an increased risk of MI and stroke in prospective studies of both apparently healthy persons and patients with preexisting arterial thrombotic disease (7-9). Subjects with plasma fibrinogen levels in the highest tertile have ~2-fold increased risk compared to those in the lowest tertile. Fibrinogen may contribute to arterial thrombotic disease via a number of mechanisms, including increased fibrin formation, plasma viscosity, platelet aggregation, and vascular endothelial smooth muscle proliferation (7). On the other hand, fibrinogen is an acute phase reactant, and the association of elevated fibrinogen and fibrinolytic protein levels with risk of arterial thrombotic disease suggests that the inflammation that accompanies atherosclerosis may contribute to increased fibrinogen levels (10). Plasma fibrinogen levels are highly correlated with other cardiovascular risk factors, such as smoking, diabetes, and estrogens (7, 11). Bezafibrate, an agent that possesses both fibrinogen-lowering and lipid-modifying properties, was associated with an overall reduction of arterial thrombotic events in a clinical trial of patients with coronary heart disease (12).

Human fibrinogen is composed of 3 pairs of polypeptide chains, α_1 and γ , encoded by 3 separate genes clustered on chromosome 4q. The synthesis of the fibrinogen β -chain is rate-limiting (13), and several β -chain polymorphisms have been associated with inter-individual variation in plasma fibrinogen levels. The -455 G/A substitution within the promoter region of the fibrinogen β -chain has been found most extensively. The -455A allele is present in about 20% of the population, who have ~10% higher fibrinogen levels compared to those with the GG genotype (14). The relationship between the -455A fibrinogen variant and risk of arterial thrombotic disease is controversial, with some case-control studies observing an association (15, 16) and other large studies finding no association (18, 19). These inconsistent findings cast doubt on a direct cause-and-effect relationship between fibrinogen levels and arterial thrombotic disorders.

Factor VII

Factor VII is a vitamin-K dependent coagulation protein, which upon activation, binds to tissue factor present in damaged vascular sub-endothelium and initiates coagulation. In the Northwick Park Heart Study, a prospective study of over 1,300 middle-aged men, plasma factor VII activity levels were associated with fatal, but not non-fatal, ischemic heart disease (20). However, several subsequent prospective studies have failed to confirm the association between factor VII levels and risk of coronary heart disease (21-23). Factor VII is also unrelated to risk of venous thrombotic disease (24). Plasma factor VII levels are determined by multiple environmental factors, including age, gender, body mass index, dietary fat, and triglyceride level (25). In addition, several intragenic factor VII polymorphisms which influence plasma factor VII levels have been described. These include an Arg353Gln substitution that is associated with decreased factor VII secretion in vitro and lower factor VII levels (26). An Italian case-control study of young adults with familial MI observed an inverse association with homozygosity of the factor VII Gln353 allele (OR = 0.08, 95% CI = 0.01-0.9) (27). In contrast, several other case-control studies involving either young men (28) or a broader age range (29-31) found no association between the Arg353Gln polymorphism and risk of MI or stroke. Thus, the evidence to date does not support factor VII at either the phenotypic or genotypic level as an important risk factor for arterial thrombotic disease.

Factor VIII and von Willebrand Factor

Increased plasma levels of factor VIII activity, von Willebrand factor (vWF) antigen, and vWF activity have been associated with incident fatal and non-fatal arterial thrombotic events in prospective studies involving healthy middle-aged (22, 23, 32, 33) and elderly (34) populations. In some studies, the associations were independent of other cardiovascular risk factors. In most prospective studies of patients with underlying atherosclerotic disease, vWF levels have been independently associated with risk of acute thrombotic events (10, 35, 36). Factor VIII and vWF circulate as a complex, and plasma levels of these two factors are highly correlated with each other. Thus, elevated factor VIII/vWF levels may be either a marker of atherosclerosis (i.e., endothelial dysfunction and vascular injury) or contribute directly to fibrin formation (factor VIII) or shear-induced platelet adhesion and aggregation (vWF). The demonstration that congenital factor VIII deficiency is associated with decreased mortality from ischemic heart disease (37, 38), as well as the association of elevated factor VIII levels with venous thrombotic disease (39), support the hypothesis of a direct effect of factor VIII concentration on the occurrence of thrombotic events. Factor VIII levels are also influenced by ABO blood group, and individuals with blood group non-O have both higher factor VIII levels and higher incidence of coronary heart disease compared to individuals with blood group O (32, 40). Further evaluation of factor VIII and cardiovascular risk awaits elucidation of other genetic determinants of increased factor VIII levels (41).

Factor XIII

Factor XIII is a transglutaminase that forms covalent bonds between adjacent fibrin monomers, and thus stabilizes a fibrin clot. Factor XIII circulates as a zymogen composed of 2 catalytic A subunits and 2 carrier B subunits. Thrombin cleavage of a 37-amino-acid N-terminal peptide results in activation of the catalytic subunit. A Val34Leu poly-

morphism of the catalytic subunit is located 3 amino acid residues from the thrombin cleavage site, and the less common Leu34 allele has been associated with increased plasma factor XIII activity levels (42, 43). Paradoxically, several recent studies suggest that the "high activity" Leu34 allele may be associated with a decreased risk of MI (44, 45), ischemic arterial stroke (46), and venous thrombotic disease (47), as well as an increased risk of hemorrhagic stroke (48). The mechanism for the apparent antithrombotic effect of the factor XIII Val/Leu34 substitution may involve an increased rate of conversion of factor XIII to activated factor XIII by thrombin that results in an altered cross-linked fibrin clot structure (49).

Levels of other Coagulation Factors

Recently, elevated levels of factor V, but not factor X or prothrombin, were associated with occurrence of MI after adjusting for other risk factors (50). Because of the retrospective nature of this study, one can not distinguish whether increased factor V activity is a cause rather than a consequence of MI. To our knowledge, the associations of levels of coagulation factors XI, X, and IX, V, and prothrombin with arterial thrombotic disease have not been assessed in prospective studies.

Inherited Thrombophilic Disorders

Protein C, Protein S, Antithrombin Deficiency

It is well-established that congenital deficiencies of protein C, protein S, and antithrombin are associated with an increased risk of venous thrombotic disease. Whether congenital deficiencies of these naturally-occurring coagulation inhibitors are associated with increased risk of arterial thrombotic disease is less clear (51, 52). In a pooled analysis of 8 small series of arterial cerebral infarction in predominantly young patients ($n = 311$), deficiencies of protein S, protein C, and antithrombin were noted in 11.9%, 2.2%, and 2.2% of cases, respectively (53). However, in many of these studies, interpretation of results is limited due to small numbers of subjects, lack of controls, lack of follow-up or family studies to document inherited vs. acquired deficiency, and population admixture. More recent studies of unselected young adults with acute cerebral ischemia suggest that acute, transient or acquired deficiencies of the naturally-occurring anticoagulants are not uncommon, but that true congenital deficiencies are rare (54-56). Several recent pediatric series suggest that protein C or protein S deficiency may be present in as many as 5-15% of children with ischemic stroke (57-59). However, in some cases true congenital deficiency has not been clearly documented, and other pediatric studies have not confirmed these associations (60, 61). Taken together, the evidence suggests that deficiencies of natural anticoagulants are likely to be associated with arterial thrombotic disease, particularly in very young individuals with acute cerebral ischemia. However, since the prevalences of these deficiencies are low even among young patients, they account for a small proportion of cases.

Activated Protein C Resistance and Factor V Leiden

Resistance to the anticoagulant effect of activated protein C is most commonly due to a nucleotide G1691A mutation in the gene encoding factor V that results in an Arg506Gln mutation (factor V Leiden). This mutation occurs at the initial activated protein C cleavage site within the factor Va heavy chain and results in a prothrombotic state because

of a reduced rate of factor Va inactivation. Factor V Leiden is the most common genetic factor associated with risk of venous thromboembolic disease, and is found in approximately 3-5% of the Caucasian population (62, 63).

A relationship between factor V Leiden and arterial thrombotic disease was first suggested by Holm et al. (64), who reported two young women (ages 33 and 34 years) with MI and homozygosity for factor V Gln506. However, most subsequent studies have failed to show an association between factor V Leiden and coronary disease or nonfatal MI (65-71), even among patients who developed acute coronary syndromes at a young age (72-74). In contrast, Rosendaal et al. (75) reported a higher risk of non-fatal MI among young female carriers of factor V Leiden (OR 2.4, 95% CI 1.0-5.9) that was particularly high among smokers (32-fold increased risk compared to nonsmoking women without the factor V mutation). In a large, case-control study of middle-aged-to-elderly Dutch men, Doggen et al. (76) also reported an increased risk of MI associated with heterozygosity for factor V Leiden (OR 1.4; 95% CI 0.8-2.2) that was most pronounced in men with other cardiovascular risk factors.

While factor V Leiden is not a risk factor for ischemic stroke in middle-aged to elderly patients (66, 68, 71, 77), some studies in younger adults (<45-50 years) indicate a higher prevalence of factor V Leiden in stroke cases than controls (56), but most show no association (78-80). In an Italian study (56), the risk of stroke associated with the factor V Leiden mutation was stronger in women than men, although a smaller North American study of exclusively young women found no association (80). In children, recent data suggests that factor V Leiden may account for approximately 20% of cases of ischemic stroke (58-60, 81).

The relationship between factor V Leiden and peripheral arterial occlusive disease has been examined in three case-control studies. In two studies, the frequency of factor V Leiden carriership was high among cases, which is higher than the population prevalence (82, 83). In contrast, a larger Austrian study of 336 patients with peripheral arterial occlusion and 300 controls observed a similar frequency of the factor V Leiden mutation between cases (8%) and controls (9%) (84).

Taken together, the cumulative results of studies examining the relationship of factor V Leiden and incident arterial thrombotic disease suggest that factor V Leiden is not a major cardiovascular risk factor, but may assume increased importance in certain patient subgroups, particularly children with arterial stroke and young women with other cardiovascular risk factors. Alternatively, the positive findings among only a few of the published studies suggests the possibility of false positive association due to population admixture. Additional association studies involving larger numbers of subjects and family-based studies that assess genetic linkage will be required to address these issues.

There is some evidence that activated protein C resistance may enhance the risk of arterial thrombotic disease even in the absence of the factor V Leiden mutation (85, 86). In a cross-sectional study of 200 men and women, carotid and femoral artery atherosclerosis as well as prevalent athero-thrombotic disease were associated with decreased response to APC (86). In this study, less than 50% of the subjects with APC resistance were carriers of the factor V Leiden mutation, suggesting that other genetic and environmental factors may contribute to the APC resistance phenotype as well as to the risk of arterial thrombotic disease (86, 87). However, the evaluation of a phenotypic association in the context of a cross-sectional study raises the issue of whether APC resistance is a consequence rather than a cause of the atherosclerotic thrombosis.

Prothrombin G20210A Mutation

Prothrombin is the circulating precursor of thrombin, which plays a central role in fibrin formation and thrombosis. A G to A transition in the prothrombin gene results in the prothrombin 20210 allele. This mutation is associated with elevated circulating prothrombin levels, and was initially identified as a risk factor for venous thromboembolic disease (88). This mutation is present in about 2% of Caucasians, but its prevalence increases from Northern to Southern Europe (89).

As with factor V Leiden, the relationship between the prothrombin 20210A mutation and risk of arterial thrombotic disease is controversial. In most of the published studies, there was no association between the presence of the 20210A allele and risk of acute MI or coronary artery disease (90-94). While these results suggest that the prothrombin 20210A mutation is not a major risk factor for coronary heart disease, the statistical power of many of these studies to detect an association is limited by the relatively low frequency of the mutation in the general population. In a pooled analysis of 1,115 patients and 1,888 controls from 10 studies, Franco et al. noted a significant association in the studies that were confined to patients with MI (OR = 2.5; 95% CI 1.5-4.3), but no association in the pooled analysis of studies that included cases with a broader range of athero-thrombotic disease (95). In the largest single case-control study of patients with MI (560 patients under the age of 70), the prothrombin 20210A allele was associated with a 50% increased risk of MI that increased substantially to 150% in the presence of traditional cardiovascular risk factors such as smoking and hypertension (76). Similarly, in a small case-control study of women <45 years old with acute MI, Rosendaal et al. reported a 2-fold increased risk of MI associated with prothrombin 20210A that was significantly enhanced in the presence of smoking or other metabolic risk factors (96).

In the majority of studies examining the relationship between prothrombin G20210A and ischemic arterial stroke in young adults (56, 76, 96) and older subjects (90, 94) have been negative. The exception is a case-control study of 72 Italian young men and women (<50 years old) with ischemic arterial stroke who did not have traditional cardiovascular risk factors (OR = 5.1, 95% CI = 1.6-16.3) (78). In a case-control study of 148 pediatric patients, the prothrombin 20210A allele was associated with a 5-fold increased risk of spontaneous ischemic arterial stroke (58), but two smaller pediatric studies found no association (61, 81). A recent case-control study found no association of the prothrombin 20210A allele with risk of peripheral arterial occlusion in an elderly patient population (84).

Taken together, the results of these studies suggest that the prothrombin 20210A mutation may be associated with a modestly increased risk of arterial thrombotic disease that may assume particular importance in certain subgroups, such as young women with MI or cerebrovascular events in children.

Platelet Receptor Polymorphisms

Glycoprotein IIb/IIIa

Glycoprotein IIb/IIIa (integrin $\alpha_{IIb}\beta_3$) is the platelet surface receptor for fibrinogen, von Willebrand factor (vWF), and several other adhesive ligands. The glycoprotein IIIa subunit consists of two common forms, PL^{A2} (HPA-1a) and PL^{A1} (HPA-1b). This dimorphism is due to a T to C nucleotide substitution involving nucleotide 1565 within exon 2 of the glycoprotein IIIa gene, and results in a Leu33/Pro33

substitution that is associated with a conformational change in the N-terminal disulfide loop of glycoprotein IIIa relative to the fibrinogen binding site (98). The allele frequency of the PL^{A2} variant ranges from ~10 to 18 percent in Caucasian populations, ~8% in African populations, and is virtually absent in Asian populations.

In 1996, Weiss et al. reported that the frequency of carrying at least one copy of the PL^{A2} allele was twice as high in 71 hospitalized patients with MI or unstable angina (39.4%) compared with 68 hospitalized control subjects (19.1%) (OR = 2.8; 95% CI = 1.2-6.4) (99). When the analysis was restricted to the subgroup of patients under the age of 60, the relative risk of acute coronary disease associated with the PL^{A2} allele increased to 6.2 (95% CI = 1.8-22.4). Since this initial report, there have been over 20 additional observational studies that have examined the relationship between the PL^{A1}/PL^{A2} polymorphism of glycoprotein IIIa and risk of acute or stable coronary artery disease. While a few of these studies have confirmed the association between the PL^{A2} allele and increased risk of early-onset coronary heart disease (73, 100-102), the majority have not. The negative studies include the 5 involving at least 300 cases (103-107). However, comparison of the results among studies is complicated by differences in definition of coronary disease, selection of control subjects, and study design. Thus, negative results observed in some studies might be expected if the association is confined to younger patients with MI and/or to specific subgroups, such as women (102), cigarette smokers (73), individuals with pre-existing coronary atherosclerosis (101), or individuals with additional genetic predispositions (108).

Of the published studies that have assessed the relationship between PL^{A2} and ischemic stroke, one (109) observed an association only in subgroups of patients under the age of 50 (OR = 1.68; 95% CI 1.00-2.82) and in non-smokers (OR = 2.37; 95% CI 1.19-4.74), and another only in a small subgroup of women (n = 18) who were white and had an identifiable etiology (110). In contrast, two other studies involving a broader age range of both men and women (111, 112), and a study of male physicians (106) found no association between the PL^{A2} variant and risk of ischemic stroke.

The assessment of the relationship between the PL^{A2} genetic variant of glycoprotein IIIa and risk of arterial thrombotic disease is also hampered by the lack of a clearly defined effect on platelet function. While some studies have demonstrated that PL^{A2}-positive platelets display increased in vitro platelet reactivity compared to PL^{A1}-negative platelets (113, 114), others have not (115, 116). The association between PL^{A2} and an increased thrombotic tendency is also supported by experiments using stable cell lines overexpressing the PL^{A1} and PL^{A2} polymorphic forms of glycoprotein IIb/IIIa (117), as well as a recent autopsy study in which the presence of the PL^{A2} allele was associated with an increased frequency of acute coronary thrombosis and complicated atherosclerotic plaques in men with fatal MI (118).

In summary, both the clinical and experimental data assessing the role of the PL^{A2} variant of glycoprotein IIIa in arterial thrombotic disease have yielded conflicting results. Additional molecular genetic and functional analysis of the platelet glycoprotein IIb/IIIa receptor, as well as studies involving larger numbers of subjects that allow stratification by other cardiovascular risk factors, will be required to resolve these issues.

Glycoprotein Ia/IIa

Glycoprotein Ia/IIa (integrin $\alpha_2\beta_1$) is the major platelet collagen receptor, and is responsible for platelet adherence to exposed vascular subendothelium. Several single nucleotide polymorphisms within the

glycoprotein Ia (α_2 integrin) subunit of the glycoprotein Ia/IIa receptor have been described. Two silent single nucleotide polymorphisms, C807T and G873A are in complete linkage disequilibrium with each other, as well as with several other single nucleotide polymorphisms located in the adjoining introns (119, 120). Among normal individuals, there is a 5-10 fold variation in the surface level of glycoprotein Ia/IIa that correlates with collagen-induced platelet adhesion and aggregation *in vitro*. The nucleotide 807T variant of glycoprotein Ia is associated with increased platelet glycoprotein Ia/IIa receptor levels and increased collagen-induced platelet adhesion compared to the 807C allele (119-121). The mechanism of the association between the 807T allele and increased receptor density is unknown. The 807T allele may be linked to another polymorphism within the glycoprotein Ia gene involving a regulatory element that controls gene transcription levels or mRNA stability.

The prothrombotic tendency of the glycoprotein Ia 807T allele is supported by four recent case-control studies. In a study of 2,237 consecutive German men undergoing coronary angiography, Santoso et al. (122) reported a higher frequency of the 807T allele in individuals who had suffered an MI compared to those without MI (OR 1.57; 95% CI 1.14-2.13) that was most pronounced in obese men under the age of 49 (OR 4.92; 95% CI 1.71-14.2). In a smaller case-control study, Moshfegh et al. reported a 3-fold increased risk of MI in individuals who carried two copies of the 807T allele compared to individuals who possessed the CC or CT genotype (OR 3.3; 95% CI 1.23-8.83) (123). Similarly, the 807T allele was associated with a 2-3 fold increased risk of ischemic stroke in men under the age of 50 (124) and women under the age of 45 (125). In contrast to these 4 positive studies, Croft et al. reported no association between glycoprotein C807T and risk of MI, either overall (OR 0.88, 95% CI 0.74-1.05), in younger individuals, or in subgroups defined by other risk factors (126). Corral et al. also reported no association between the 807T allele and risk of either acute coronary heart disease or ischemic stroke in a middle-aged to elderly study population (121). Furthermore, it should be noted that the frequency of 807TT homozygotes among the control group of one of the positive studies (5.6%) was considerably lower than other published population studies (123). In summary, preliminary results suggest that the 807T variant of glycoprotein Ia may be a genetic risk factor for early-onset arterial thrombotic disease, but further studies involving larger numbers of subjects, as well as further characterization of the mechanism responsible for increased receptor levels, are required to settle this issue.

Glycoprotein Ib/IX

Glycoprotein Ib/IX receptor is the major platelet receptor for von Willebrand factor. Two polymorphisms that affect the amino acid sequence of the glycoprotein Ib heavy chain (glycoprotein Ib α) have been described. The first, an ACG to ATG substitution at codon 145, results in a Thr/Met dimorphism that is responsible for the human platelet antigen (HPA)-2 system. The second is a size polymorphism that results from a variable number of tandem repeats (VNTR) of a 13-amino-acid sequence (Ser399-Thr411) that is present in either one (D), two (C), three (B), or four (A) copies (127). The HPA-2 and VNTR polymorphisms are in strong linkage disequilibrium with each other. The HPA-2 Thr145Met dimorphism results in a protein conformational change in a region adjacent to the vWF binding region of glycoprotein Ib α , but an effect on *in vitro* platelet function or von Willbebrand factor binding has not been demonstrated (128, 129). The VNTR polymorphism involves the macroglycopeptide region of glycoprotein Ib α ,

with the addition of each repeat resulting in an increased distance between the ligand binding region and the platelet surface. While it has been hypothesized that this distance variation may affect platelet susceptibility to shear-induced activation (127), this has yet to be demonstrated experimentally.

Despite the lack of an associated prothrombotic phenotype, several case-control studies have noted a 2-3 fold increased risk of coronary heart disease or stroke associated with the Met145 (HPA-2b) or VNTR-B allele, particularly in younger patients (130-132). In contrast, Ardissino et al. did not find an association between the HPA-2 polymorphism and premature MI in a case-control study involving predominantly men (73). Two other studies did not observe an association between HPA-2 or VNTR genotypes and risk of ischemic stroke in older patient populations (109, 112).

Other Hemostatic Factors

Fibrinolytic System

The fibrinolytic system consists of the circulating proenzyme plasminogen, which is converted to plasmin by the plasminogen activators, tPA and urokinase. Plasminogen activator inhibitor-1 (PAI-1) is a major inhibitor of the fibrinolytic system, and is synthesized by a variety of cell types, including platelets, endothelial cells, and vascular smooth muscle cells. Data from several prospective studies indicate an association between plasma levels of various fibrinolytic markers (i.e. tPA antigen, PAI-1 activity and antigen levels, and fibrin degradation products) and risk of arterial thrombotic disease (133-137). The presence of increased levels of PAI-1 mRNA in atherosclerotic plaques (138) and the association of elevated plasma PAI-1 levels with subclinical atherosclerosis (139) also suggest a role for impaired fibrinolysis in the occurrence of athero-thrombotic disease. However, this role is complex: inhibition of fibrinolysis may promote thrombosis, but also may inhibit matrix metalloendopeptidase activation and vascular smooth muscle proliferation, which may alter atherosclerotic plaque stability (140).

The interpretation of cardiovascular epidemiologic studies of fibrinolytic markers is complicated by several other factors. Plasma tPA antigen and PAI-1 activity levels are highly correlated, in part because the tPA antigen assay measures both free tPA and tPA complexed to PAI-1, which increases in patients with high PAI-1 levels due to delayed clearance (141). Measurement and interpretation of plasma PAI-1 activity levels are particularly problematic due to diurnal variation, spontaneous transformation of PAI-1 to an inactive or latent form at neutral pH, and the potential for release of PAI-1 from platelets; these necessitate special measures during blood collection and sample processing (142). PAI-1 is also an acute phase reactant, and circulating levels are influenced by a number of hormones and cytokines (143). Increased PAI-1 levels are also correlated with obesity, hyperinsulinemia, and hypertriglyceridemia, (i.e., the "insulin resistance syndrome"). Thus, in most epidemiologic studies, the association between PAI-1, tPA levels and risk of arterial thrombotic disease may be confounded by these other cardiovascular risk factors.

The 4G allele of the 4G/5G polymorphism located within the promoter region of the PAI-1 gene has been associated with increased cytokine-induced gene transcription *in vitro* (143) due differential binding of a transcriptional repressor (144), and increased plasma PAI-1 levels in most studies (140). While several case-control studies have demonstrated an increased risk of MI or coronary artery disease associated

and with the 4G allele (144-146), these findings have not been confirmed in several larger studies (147-149). A meta-analysis of nine studies that included 1,521 cases and 2,120 controls indicated an overall slightly increased risk of MI associated with the 4G allele (OR 1.23, 95% CI 1.04-1.45) (150). However, the increased risk was confined to the subgroup of case-control studies in which both cases and controls were taken from "high-risk" populations.

Homocysteine

Homocysteine is a sulfur-containing amino acid that is formed as an intermediary compound during methionine metabolism. Congenital homocystinuria, a rare autosomal recessive metabolic disorder, is associated with very high levels ($>100 \mu\text{mol/L}$) of fasting plasma total homocysteine, and is often accompanied by premature thrombotic disease involving the coronary, cerebral, and peripheral arteries. Mild hyperhomocysteinemia (i.e., $>15 \mu\text{mol/L}$) is not uncommon in the general population, and is associated with a variety of acquired and genetic factors, including increasing age, male sex, cigarette smoking, reduced consumption of nutritional factors (folate, vitamin B₆, vitamin B₁₂), renal failure, and heterozygous deficiencies of enzymes involved in homocysteine metabolism (151, 152). The adverse effects of homocysteine include vascular endothelial injury, smooth muscle proliferation, oxidation of low-density lipoprotein cholesterol, and induction of a prothrombotic vascular endothelial microenvironment (151, 152).

Since the very high levels of plasma homocysteine that accompany congenital homocystinuria are strongly related to risk of arterial thrombotic disease, some degree of association with mildly elevated levels is also plausible. There have been a number of case-control and cross-sectional studies that indicate that mild hyperhomocysteinemia is associated with an increased risk of coronary heart disease, cerebrovascular disease, and peripheral vascular disease (153-155). However, it should be noted that homocysteine levels may increase following acute arterial thrombosis (156, 157), which complicates the interpretation of studies in which levels are measured retrospectively. Prospective studies assessing the risk of arterial thrombotic disease associated with elevated homocysteine levels have yielded mixed results with most studies showing a weak or no association (154, 155). The strongest associations have tended to occur in studies involving subjects with pre-existing cardiovascular disease. This raises the issue of whether the elevated homocysteine levels are a consequence rather than a cause of clinical atherosclerosis.

Mild hyperhomocysteinemia has been associated with a thermolabile variant of MTHFR that is due to a C to T transition at nucleotide 677. Homozygosity for the C677T MTHFR variant is present in 5% to 10% of Caucasians. A recent meta-analysis of 23 case-control studies including over 12,000 subjects concluded that homozygosity for the thermolabile MTHFR variant is not associated with risk of cardiovascular disease (158). This absence of an association raises doubt about the role of mild hyperhomocysteinemia as a cause of arterial thrombotic disease. However, based on the association of MTHFR and homocysteine levels, the predicted relative risk of the thermolabile MTHFR genotype is small (possibly no more than a 20-percent risk increase), and even a meta-analysis may have insufficient power to detect a risk of this magnitude. Ongoing randomized clinical trials of folic acid and B vitamin supplementation to reduce plasma homocysteine levels should provide more definitive answers to the public health questions surrounding homocysteine and risk of athero-thrombotic disease.

Lipoprotein (a)

Lp(a) is a complex serum lipoprotein composed of an LDL particle linked by its surface apolipoprotein (apo) B-100 via a disulfide bond to a unique and highly polymorphic glycoprotein, apo(a) (159). Apo(a) shares extensive structural homology with plasminogen, and consists of a non-functional serine protease domain, a variable number of multiple repeats of kringle IV, and a single copy of kringle V. The variable number of kringle IV repeats is due to varying number of copies within the apo(a) gene, and results in at least 35 different molecular weight isoforms.

Plasma Lp(a) levels are largely genetically determined (160), and vary inversely with apo(a) isoform size. Levels increase in patients with renal disease, and are lower in white populations compared to African Americans (161). In contrast to plasma LDL levels, Lp(a) levels are unaffected by diet, physical activity, and most lipid-lowering agents. On the other hand, estrogen replacement therapy and high-dose niacin can lower plasma Lp(a) levels.

Experimental evidence suggests that Lp(a) may contribute to the occurrence of arterial thrombotic disease through effects on both atherosclerosis and thrombosis (159). Oxidized Lp(a) can be internalized by macrophages and contribute to delivery of cholesterol to sites of vessel injury. Because of its structural similarity to plasminogen, Lp(a) inhibits plasminogen binding to fibrin and endothelial cells (162), and thereby interferes with fibrinolysis and promotes thrombosis (163). Lp(a) accumulates in atherosclerotic lesions, and has been implicated in the progression of coronary atherosclerosis (164). Lp(a) may also impair endothelial function and induce smooth muscle proliferation.

Despite these experimental data, clinical data supporting the role of Lp(a) as a cardiovascular risk factor are controversial. A number of studies have shown an association between elevated Lp(a) levels and increased risk of coronary, cerebrovascular, and peripheral arterial disease (161, 165, 166). However, like homocysteine, Lp(a) levels increase following an acute thrombotic event. Thus, retrospective studies may not be able to discern whether elevated Lp(a) levels are the cause or consequence of cardiovascular disease, and prospective studies have yielded conflicting results (167-174). Based on the cumulative epidemiologic data, if an association between Lp(a) levels and cardiovascular disease exists, the effect is likely to be small and confined to a small proportion of the population with the very highest serum levels (175), onset at a young age (170) or those with additional dyslipidemias (167, 174, 176, 177). Further evaluation of the significance of apo(a) isoform size on the occurrence of athero-thrombotic disease (171, 177) as well as other genetic mechanisms that underlie Lp(a) heterogeneity (178) may lead to improvements in the use of Lp(a) as a determinant of cardiovascular risk.

Thrombomodulin

Thrombomodulin is an endothelial cell surface receptor for thrombin that functions as an anticoagulant by greatly accelerating thrombin-induced activation of protein C. A soluble, truncated form of thrombomodulin circulates in plasma, but its significance is unknown. In a large prospective case-cohort study, decreased plasma thrombomodulin levels were associated with an increased risk of MI (179). Some reports have suggested that several rare polymorphisms within the thrombomodulin promoter and coding sequence may be related to risk of MI (180-182).

Recommendations for Screening

Despite the proliferation of epidemiologic studies, increased fibrinogen level remains the only hemostatic biomarker that has been clearly identified as a risk factor for arterial thrombotic disease. And even for fibrinogen one may question the causality of the association. The decision whether to perform screening for a hemostatic marker, however, should be based on whether screening offers a cost-effective way of identifying individuals who would benefit from treatment. Therefore, screening of plasma fibrinogen is generally not advocated because levels are favorably affected by modification of other risk factors (e. g., smoking cessation, exercise, and post-menopausal hormone replacement therapy) and because a beneficial effect of lowering fibrinogen level on cardiovascular risk has yet to be demonstrated. There is some epidemiologic and biologic evidence that elevated plasma levels of factor VIII, homocysteine, and Lp(a), as well as several genetic hemostatic variants (factor V Leiden, factor XIII Leu34, prothrombin G20210A, the PL^{A2} variant of glycoprotein IIIa, and glycoprotein Ia 807T) are related to the occurrence of arterial thrombosis. However, there is currently no evidence that screening for any of the above hemostatic markers either within the general population or among subgroups, such as individuals who develop arterial thrombotic disease at a young age, would have any prognostic or therapeutic consequences. Several inherited conditions associated with venous thrombosis (deficiencies of protein C, protein S or antithrombin, factor V Leiden, and prothrombin G20210A) are not as important in the overall occurrence of arterial thrombosis, except possibly in subgroups such as the very young or premenopausal women. Thus, evaluation of these disorders in the setting of arterial thrombosis may be considered in young patients once more likely candidates (lipid disorders, hyperhomocystenemia, lupus anticoagulant/antiphospholipid antibody syndrome) have been excluded, or in MI patients without significant coronary atherosclerosis (183). In addition, a thrombin time and fibrinogen level should be obtained in these young patients to exclude congenital dysfibrinogenemia, another rare cause of both venous and arterial thrombophilia (184).

Conclusion

With the progression of the human genome project and the recent focus on identification of inter-individual genetic variation, the potential for evaluating the relationship between functional variants of candidate genes, associated prothrombotic phenotypes, and risk of arterial thrombotic disease will greatly increase. Several guidelines for future studies that evaluate novel hemostatic markers should be considered. First, molecular epidemiologic studies should focus on genetic mutations that are associated with clearly defined effects on hemostatic function and that contribute significantly to inter-individual phenotypic variation. Second, examination of homogenous populations and precise, well-defined clinical outcomes should enhance the ability to detect associations. For example, hereditary determination by as yet unidentified genetic factors may be particularly important in MI that occurs at younger ages and in women (185). Furthermore, restriction to ethnically homogeneous populations or eliciting detailed information regarding genetic ancestry from study subjects should minimize the problem of false positive associations arising from population admixture. In addition, any preliminary associations observed in population-based studies should be complemented with family-based studies that provide evidence that the marker of interest is genetically linked to the disease (186). Third, large sample sizes will be required to provide enough statistical power to assess the interaction of genetic susceptibility mark-

ers with other genetic and environmental risk factors. Undoubtedly, other candidate genes and associated functional polymorphisms involved in arterial thrombotic disease will continue to be identified. Integration of knowledge involving novel hemostatic biomarkers at the genetic, biochemical, and clinical-epidemiologic levels should lead to significant developments in understanding the pathophysiology of arterial thrombotic disease, the assessment of cardiovascular risk, and the targeting of specific antithrombotic therapies to high-risk individuals.

References

1. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. *Circulation* 1996; 94: 2013-20.
2. Rentrop KP. Thrombi in acute coronary syndromes. Revisited and revised. *Circulation* 2000; 101: 1619-26.
3. Grover SA, Coupal L, Hu XP. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? *JAMA* 1995; 274: 801-6.
4. Hebert PR, Ridker PM, Fuster V, Hennekens CH. Antithrombotic therapy in the secondary and primary prevention of cardiovascular diseases in high and usual risk individuals. In: *Cardiovascular Thrombosis: Thrombogenesis and Thrombolysis*. Verstraete M, Fuster V, Topol EJ, eds. Philadelphia: Lippincott-Raven Publishers 1998: 461-70.
5. Ridker PM. Novel risk factors and markers for coronary disease. *Ann Intern Med* 2000; 45: 391-417.
6. Kullo JJ, Gau GT, Tajik AJ. Novel risk factors for atherosclerosis. *Clin Proc* 2000; 75: 369-80.
7. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. *Ann Intern Med* 1993; 118: 956-61.
8. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. Meta-analysis of prospective studies. *JAMA* 1998; 279: 1477-82.
9. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. An update. *Arterioscler Thromb Vasc Biol* 1999; 19: 1368-77.
10. Thompson SG, Kienast J, Pyke SDM, Haverkate F, van de Loo JKB. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. *N Engl J Med* 1995; 332: 635-41.
11. Folsom AR. Fibrinogen and cardiovascular risk markers. *Blood Coagul Fibrinol* 1999; 10: S13-S15.
12. Behar S. Lowering fibrinogen levels: clinical update. *Blood Coagul Fibrinol* 1999; 10: S41-S43.
13. Roy SN, Mukhopadhyay G, Redman CM. Regulation of fibrinogen assembly. Transfection of hepG2 cells with B β cDNA specifically enhances synthesis of the three component chains of fibrinogen. *J Biol Chem* 1990; 265: 6389-93.
14. Humphries SE, Henry JA, Montgomery HE. Gene-environment interaction in the determination of levels of haemostatic variables involved in thrombosis and fibrinolysis. *Blood Coagul Fibrinol* 1999; 10: S18-S21.
15. Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambien F, J-P. Scarabin P-Y, Bara L, Green F, Cambien F. β -fibrinogen gene polymorphisms are associated with plasma fibrinogen and coronary artery disease in patients with myocardial infarction: the ECTIM study. *Circulation* 1996; 93: 440-9.
16. Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of the fibrinogen B β 448 polymorphism, fibrinogen level, and acute coronary disease. *Arterioscler Thromb Vasc Biol* 1997; 17: 1111-1116.
17. Nishiuma S, Kario K, Yakushijin K, Maeda M, Murai R, Matsuo M, U. Shimada K, Matsuo M. Genetic variation in the promoter region of the β -fibrinogen gene is associated with ischemic stroke in a Japanese population. *Blood Coagul Fibrinol* 1998; 9: 373-9.
18. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Arsenault B, Schnohr P, Nordestgaard BG. A common mutation (G-455A) in the

- fibrinogen promoter is an independent predictor of plasma fibrinogen. A study of 9,127 individuals based on the Framingham City Heart Study. *J Clin Invest* 1997; 99: 3034-9.
34. Rosendaal FR, Blann AD, Waas W, Eberbach A, Schwartz O, Haberbosch W, Katz N, Weiss T, Tillmanns A, Verheij AB, Verhagen HW, Waas W, Eberbach A. Positive association of the β fibrinogen gene H1/H2 gene variation to basal fibrinogen levels and to increase in fibrinogen concentration during acute phase reaction but not to coronary artery disease and myocardial infarction. *Thromb Haemost* 1997; 77: 107-11.
35. Ruddle RW, Ruddock V, Stirling Y, Chakrabati R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. *Lancet* 1993; 342: 1076-9.
36. Verhagen HW, Heinrich J, Schulte H, van de Loo J, Assmann G. Coagulation factor VII and the risk of coronary heart disease in healthy men. *Arterioscler Thromb Vasc Biol* 1997; 17: 1539-44.
37. Lee AJ, Fowkes FGR, Price JF, Rumley A, Lowe GDO. Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. *Arterioscler Thromb Vasc Biol* 1997; 17: 3321-5.
38. Verhagen HW, Wu KK, Rosamond WD, Sharrett AR, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. The Atherosclerosis Risk in Communities (ARIC) study. *Circulation* 1997; 96: 1102-8.
39. Verhagen HW, Rosendaal FR, Reitsma PH, van der Velden PA, Briët E, Vandenbroucke JP. Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). *Thromb Haemost* 1994; 71: 719-22.
40. Meade TW, Schouten EG, Grobbee DE, Kluft C. Coagulation factor VII, dietary fat and blood lipids: a review. *Thromb Haemost* 1996; 76: 492-9.
41. Hanault M, Arbini AA, Lopaciuk S, Carew JA, Bauer KA. The Arg353Gln polymorphism reduces the level of coagulation factor VII. In vivo and in vitro studies. *Arterioscler Thromb Vasc Biol* 1997; 17: 2825-9.
42. Iacoviello L, Di Castelnuovo A, de Knijff P, D'Orazio A, Amore C, Arboreli R, Kluft C, Donati MB. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. *N Engl J Med* 1998; 338: 58-65.
43. Moor E, Silveira A, van't Hooft F, Suontaka AM, Eriksson P, Blombäck M, Hamsten A. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype. *Arterioscler Thromb Vasc Biol* 1995; 15: 655-64.
44. Lane A, Green F, Scarabin PY, Nicaud V, Bara L, Humphries S, Evans A, Luc G, Cambou JP, Arveiler D, Cambie F. Factor VII Arg/Gln353 polymorphism determines factor VII coagulant activity in patients with myocardial infarction (MI) and control subjects in Belfast and France but is not a strong indicator of MI risk in the ECTIM study. *Atherosclerosis* 1996; 119: 119-27.
45. Doggen CJM, Manger Cats V, Bertina RM, Reitsma PH, Vandenbroucke JP, Rosendaal FR. A genetic propensity to high factor VII is not associated with the risk of myocardial infarction in men. *Thromb Haemost* 1998; 80: 281-5.
46. Heywood DM, Carter AM, Catto AJ, Bamford JM, Grant PJ. Polymorphisms of the factor VII gene and circulating FVIIc levels in relation to acute cerebrovascular disease and post stroke mortality. *Stroke* 1997; 28: 216-21.
47. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ. Factor VIII, ABO blood group, and the incidence of ischaemic heart disease. *Br J Haematol* 1994; 88: 601-7.
48. Rumley A, Lowe GDO, Sweetnam PM, Yarnell JWG, Ford RP. Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart Study. *Br J Haematol* 1999; 105: 110-6.
49. Tracy RP, Arnold AM, Ettinger W, Fried L, Meilahn E, Savage P. The relationship of fibrinogen and factors VII and VIII to incident cardiovascular disease and death in the elderly. Results from the Cardiovascular Health Study. *Arterioscler Thromb Vasc Biol* 1999; 19: 1776-83.
50. Jansson JH, Nilsson TK, Johnson O, von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. *Br Heart J* 1991; 66: 351-5.
51. Blann AD, McCollum CN. Von Willebrand factor and soluble thrombomodulin as predictors of adverse events among subjects with peripheral or coronary atherosclerosis. *Blood Coagul Fibrinol* 1999; 10: 375-80.
52. Rosendaal FR, Vreke I, Brocker-Vriends AH, van Dijk H, Vandenbroucke JP, Hermans J, Suurmeijer TPBM, Briët E. Mortality and causes of death in Dutch haemophiliacs, 1973-1986. *Br J Haematol* 1989; 71: 71-6.
53. Triemstra M, Rosendaal FR, Smit C, Van der Ploeg HM, Briët E. Mortality in patients with hemophilia. Changes in a Dutch population from 1986 to 1992 and 1973 to 1986. *Ann Intern Med* 1995; 123: 823-7.
54. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-venous thrombosis. *Lancet* 1995; 345: 152-5.
55. Medalie JH, Levene C, Papier C, Goldbourt U, Dreyfus F, Oron D, Neufeld H, Riss E. Blood groups, myocardial infarction and angina pectoris among 10,000 adult males. *N Engl J Med* 1971; 285: 1348-53.
56. Kamphuisen PW, Houwing-Duistermaat JJ, van Houwelingen HC, Eikenboom J, Bertina RM, Rosendaal FR. Familial clustering of factor VIII and von Willebrand factor levels. *Thromb Haemost* 1998; 79: 323-7.
57. Kangsadalamai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. *Blood* 1998; 8: 2766-70.
58. Kohler HP, Ariëns RAS, Whitaker P, Grant PJ. A common coding polymorphism in the FXIII A-subunit gene (FXIII Val34Leu) affects cross-linking activity. *Thromb Haemost* 1998; 80: 704.
59. Kohler HP, Stickland MH, Ossei-Gernig N, Carter A, Mikkola H, Grant PJ. Association of a common polymorphism in the factor XIII gene with myocardial infarction. *Thromb Haemost* 1998; 79: 8-13.
60. Wartiovaara U, Perola M, Mikkola H, Tötterman K, Savolainen V, Penttilä A, Grant PJ, Tikkanen MJ, Vartiainen E, Karhunen PJ, Peltonen L, Palotie A. Association of FXIII Val34Leu with decreased risk of myocardial infarction in Finnish males. *Atherosclerosis* 1999; 142: 295-300.
61. Elbaz A, Poirier O, Canaple S, Chedru F, Cambien F, Amarengo P. The association between the Val34Leu polymorphism in the factor XIII gene and brain infarction. *Blood* 2000; 95: 586-91.
62. Catto AJ, Kohler HP, Coore J, Mansfield MW, Stickland MH, Grant PJ. Association of a common polymorphism in the factor XIII gene with venous thrombosis. *Blood* 1999; 93: 906.
63. Catto AJ, Kohler HP, Bannan S, Stickland M, Carter A, Grant PJ. Factor XIII Val34Leu: a novel association with primary intracerebral hemorrhage. *Stroke* 1998; 29: 813-816.
64. Ariëns RAS, Phillippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. *Blood* 2000; 96: 988-95.
65. Redondo M, Watzke HH, Stucki B, Sulzer I, Demarmels Biasiutti F, Binder BR, Furlan M, Lämmle B, Wuillermin. Coagulation factors II, V, VII, and X, prothrombin gene 20210G→A transition, and factor V Leiden in coronary artery disease. *Arterioscler Thromb Vasc Biol* 1999; 19: 1020-5.
66. De Stefano V, Leone G, Mastrangelo S, Tripodi A, Rodeghiero F, Castaman G, Barbui T, Finazzi G, Bizzzi B, Mannucci PM. Clinical manifestations and management of inherited thrombophilia: retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. *Thromb Haemost* 1994; 72: 352-8.
67. Zöller B, de Frutos PG, Dahlbäck B. A common 4G allele in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene as a risk factor for pulmonary embolism and arterial thrombosis in hereditary protein S deficiency. *Thromb Haemost* 1998; 79: 802-7.

53. Barinagarrementeria F, Cantú-Brito C, De La Peña A, Izaguirre R. Prothrombotic states in young people with idiopathic stroke. A prospective study. *Stroke* 1994; 25: 287-90.
54. Douay X, Lucas C, Caron C, Goudemand J, Leys D. Antithrombin, protein C, and protein S levels in 127 consecutive young adults with ischemic stroke. *Acta Neurol Scand* 1998; 98: 124-7.
55. Munts AG, van Genderen PJJ, Dippel DWJ, van Kooten F, Koudstaal PJ. Coagulation disorders in young adults with acute cerebral ischemia. *J Neurol* 1998; 245: 21-5.
56. Margaglione M, D'Andrea G, Giuliani N, Brancaccio V, De Lucia D, Grandone E, De Stefano V, Tonali PA, Di Minno G. Inherited prothrombotic conditions and premature ischemic stroke. Sex differences in the association with factor V Leiden. *Arterioscler Thromb Vasc Biol* 1999; 19: 1751-6.
57. Bonduel M, Sciuccati G, Hepner M, Torres AF, Pieroni G, Frontroth JP. Prothrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. *Arch Neurol* 1999; 56: 967-71.
58. Nowak-Göttl U, Sträter R, Heinecke A, Junker R, Koch HG, Schuierer G, von Eckardstein. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin, and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. *Blood* 1999; 94: 3678-82.
59. Kenet G, Sadetzki S, Murad H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. *Stroke* 2000; 31: 1283-8.
60. Ganesan V, McShane MA, Liesner R, Cookson J, Hann I, Kirkham FJ. Inherited prothrombotic states and ischaemic stroke in childhood. *J Neurol Neurosurg Psychiatry* 1998; 65: 508-11.
61. McColl MD, Chalmers EA, Thomas A, Sproul A, Healey C, Rafferty I, McWilliam R, Euson P. Factor V Leiden, prothrombin 20210 G→A and the MTHFR C677T mutations in childhood stroke. *Thromb Haemost* 1999; 81: 690-4.
62. Koster T, Rosendaal F, de Ronde H, Briët E, Vandenbrouke J, Bertina R. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. *Lancet* 1993; 342: 1503-6.
63. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. *Nature* 1994; 369: 64-7.
64. Holm J, Zöller B, Svensson PJ, Berntorp E, Erhardt L, Dahlbäck B. Myocardial infarction associated with homozygous resistance to activated protein C. *Lancet* 1994; 344: 952-3.
65. Emmerich J, Poirier O, Evans A, Marques-vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg506 to Gln factor V mutation, and activated protein C resistance. *Lancet* 1995; 345: 321.
66. Kontula K, Ylikorkala A, Miettinen H, Vuorio A, Kauppinen-Mäkelin R, Hämäläinen L, Palomäki H, Kaste M. Arg506Gln factor V mutation in patients with ischaemic cerebrovascular disease and survivors of myocardial infarction. *Thromb Haemost* 1995; 73: 558-60.
67. Prohaska W, Mannebach H, Schmidt M, Gleichmann U, Kleesiek K. Evidence against heterozygous coagulation factor V 1691 GA mutation for coronary artery disease and myocardial infarction. *J Molec Med* 1995; 73: 521-4.
68. Cushman M, Rosendaal FR, Psaty BM, Cook EF, Valliere J, Kuller LH, Tracy RP. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly: results from the Cardiovascular Health Study. *Thromb Haemost* 1998; 79: 912-5.
69. Dunn ST, Roberts CR, Schecter E, Moore WE, Lee ET, Eichner JE. Role of factor V Leiden mutation in patients with angiographically demonstrated coronary artery disease. *Thromb Res* 1998; 91: 91-9.
70. Gardemann A, Arsic T, Katz N, Tillmanns H, Hehrlein FW, Haberbosch W. The factor II G20210A and factor V G1691A gene transitions and coronary heart disease. *Thromb Haemost* 1999; 81: 208-13.
71. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. *N Engl J Med* 1995; 332: 912-7.
72. Van Bockxmeer FM, Baker RI, Taylor RR. Premature ischaemic heart disease and the gene for coagulation factor V. *Nat Med* 1995; 1: 185.
73. Ardissino D, Mannucci PM, Merlini PA, Duca F, Fetiche R, Tagliabue G, Tubaro M, Galvani M, Ottani F, Ferrario M, Corral J, Margaglione M. Prothrombotic genetic risk factors in young survivors of myocardial infarction. *Blood* 1999; 94: 46-51.
74. Vargas M, Soto I, Pinto CR, Urgelles MF, Batalla A, Rodriguez-Regueiro J, Cortina A, Alvarez V, Coto E. The prothrombin 20210A allele and the factor V Leiden are associated with venous thrombosis but not with coronary artery disease. *Blood Coagul Fibrinol* 1999; 10: 39-41.
75. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT, Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. *Blood* 1997; 89: 2817-21.
76. Doggen CJM, Manger Cats V, Bertina RM, Rosendaal FR. Interaction: coagulation defects and cardiovascular risk factors: increased risk of myocardial infarction associated with factor V Leiden or prothrombin 20210A. *Circulation* 1998; 97: 1037-41.
77. Catto A, Carter A, Ireland H, Bayston TA, Phillippou H, Barrett J, Lee DA, Grant PJ. Factor V Leiden gene mutation and thrombin generation: relation to development of stroke. *Arterioscler Thromb Vasc Biol* 1995; 15: 783-5.
78. De Stefano V, Chiusolo P, Paciaroni K, Casorelli I, Rossi E, Molinaro V, Servidei S, Tonali PA, Leone G. Prothrombin G20210A mutant gene is a risk factor for cerebrovascular ischemic disease in young patients. *Blood* 1998; 91: 3562-5.
79. Voetsch B, Damasceno BP, Camargo ECS, Massaro A, Bacheschi H, Scaff M, Annichino-Bizzachi JM, Arruda VR. Inherited thrombophilia: a risk factor for the development of ischemic stroke in young adults. *Thromb Haemost* 2000; 83: 229-33.
80. Longstreth WT Jr, Rosendaal FR, Siscovick DS, Vos HL, Schwartz SM, Psaty BM, Raghunathan TE, Koepsell TD, Reitsma PH. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). *Stroke* 1998; 29: 577-80.
81. Zenz W, Bodó Z, Plotho J, Streif W, Male C, Bernert G, Radtke Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Pöschl G, Höfler G, Mannhalter C, Muntean W. Factor V Leiden and prothrombin gene G20210A variant in children with ischemic stroke. *Thromb Haemost* 1998; 80: 763-6.
82. Foley PWX, Irvine CD, Standen GR, Morse C, Smith FT, McGee B, Baird RN, Lamont PM. Activated protein C resistance, factor V Leiden, and peripheral vascular disease. *Cardiovasc Surg* 1997; 5: 157-60.
83. Sampram ESK, Lindblad B, Dahlbäck B. Activated protein C resistance in patients with peripheral vascular disease. *J Vasc Surg* 1998; 28: 224-7.
84. Renner W, Köppel H, Brodmann M, Pabst E, Schallmoser K, Tschopp Wascher TC, Pilger E. Factor II G20210A and factor V G1691A mutations and peripheral arterial occlusive disease. *Thromb Haemost* 2000; 83: 20-2.
85. Van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. *Ann Intern Med* 1999; 130: 265-9.
86. Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer F, Oberhollenzer F, Mayr A, Gasperi A, Poewe W, Willert J. Resistance to activated protein C as a prominent risk predictor of advanced atherosclerosis and arterial disease. *Circulation* 1999; 99: 614-9.
87. Souto JC, Almasy L, Borrell M, Gari M, Martinez E, Mateo J, Blangero J, Fontcuberta J. Genetic determinants of hemostasis in Spanish families. *Circulation* 2000; 101: 1546-51.
88. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common mutation in the 3'-untranslated region of the prothrombin gene associated with elevated plasma prothrombin levels and an increased risk of thrombosis. *Blood* 1996; 88: 3698-703.

- Rosendaal FR, Doggen CJM, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH. Geographic distribution of the 20210 G to A prothrombin variant. *Thromb Haemost* 1998; 79: 706-8.
- Corral J, Gonzalez-Conejero R, Lozano ML, River J, Heras I, Vicente V. The venous thrombosis risk factor 20210A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. *Br J Haematol* 1997; 99: 304-7.
- Eikelboom JW, Baker RI, Parsons R, Taylor RR, van Bockxmeer FM. No association between the 20210 G/A prothrombin gene mutation and premature coronary artery disease. *Thromb Haemost* 1998; 80: 878-80.
- Prohaska W, Schmidt M, Mannebach H, Gleichmann U, Klecsiek K. The prevalence of the prothrombin 20210 G→A mutation is not increased in angiographically confirmed coronary artery disease. *Thromb Haemost* 1999; 81: 161-2.
- Croft SA, Daly ME, Steeds RP, Channer KS, Samani NJ, Hampton KK. The prothrombin 20210A allele and its association with myocardial infarction. *Thromb Haemost* 1999; 81: 861-4.
- Ridker PM, Hennekens CH, Miletich JP. G20210A mutation in prothrombin gene and risk of myocardial infarction, stroke, and venous thrombosis in a large cohort of US men. *Circulation* 1999; 99: 999-1004.
- Franco RF, Trip MD, ten Cate H, van den Ende A, Prins MH, Kastelein JJP, Reitsma PH. The 20210 G→A mutation in the 3'-untranslated region of the prothrombin gene and the risk for arterial thrombotic disease. *Br J Haematol* 1999; 104: 50-4.
- Rosendaal FR, Siscovick DS, Schwartz SM, Psaty BM, Raghunathan TE, Vos HL. A common prothrombin variant (20210 G to A) increases the risk of myocardial infarction in young women. *Blood*. 1997; 90: 1747-50.
- Bentolila S, Ripoli L, Drouet L, Mazoyer E. Thrombophilia due to 20210 G→A prothrombin polymorphism and cerebral ischemia in the young. *Stroke* 1997; 28: 1846.
- Honda S, Honda Y, Bauer B, Ruan C, Kunicki TJ. The impact of three-dimensional structure on the expression of P1A alloantigens on human integrin β_3 . *Blood* 1995; 86: 234-42.
- Weiss EJ, Bray PF, Tayback M, Schulman SP, Kickler TS, Becker LC, Weiss JL, Gerstenblith G, Goldschmidt-Clermont PJ. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. *N Engl J Med* 1996; 334: 1090-4.
- Carter AM, Ossei-Gerning N, Wilson IJ, Grant PJ. Association of the platelet P1A polymorphism of glycoprotein IIb/IIIa and the fibrinogen BB 448 polymorphism with myocardial infarction and extent of coronary artery disease. *Circulation* 1997; 96: 1424-31.
- Zotz RB, Winkelmann BR, Nauck M, Giers G, Maruhn-Debowski B, Marz W, Scharf RE. Polymorphism of platelet membrane glycoprotein IIIa: Human platelet antigen 1b (HPA-1b/P1A²) is an inherited risk factor for premature myocardial infarction in coronary artery disease. *Thromb Haemost* 1998; 79: 731-5.
- Pastinen T, Perola M, Niini P, Terwilliger J, Salomaa V, Vartiainen E, Peltonen L, Syvänen AC. Array-based multiplex analysis of candidate genes reveals two independent and additive genetic risk factors for myocardial infarction in the Finnish population. *Hum Molec Genet* 1998; 7: 1453-62.
- Herrmann S-M, Poirier O, Marques-Vidal P, Evans A, Arveiler D, Luc G, Emmerich J, Cambien F. The *Leu³³/Pro* polymorphism (P1A¹/P1A²) of the glycoprotein IIIa (GPIIIa) receptor is not related to myocardial infarction in the ECTIM Study. *Thromb Haemost* 1997; 77: 1179-81.
- Laule M, Cascorbi I, Stangl V, Bielecke C, Wernecke KD, Mrozikiewicz PM, Felix SB, Roots I, Baumann G, Stangl K. A1/A2 polymorphism of glycoprotein IIIa and association with excess procedural risk for coronary catheter intervention: a case-controlled study. *Lancet* 1999; 353: 708-12.
- Böttiger C, Kastrati A, Koch W, Mehili J, Seidl H, Schömig K, von Beckerath N, Schömig A. HPA-1 and HPA-3 polymorphisms of the platelet fibrinogen receptor and coronary artery disease and myocardial infarction. *Thromb Haemost* 2000; 83: 559-62.
- Ridker PM, Hennekens CH, Schmitz C, Stampfer MJ, Lindpaintner K. P1A¹/A² polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. *Lancet* 1997; 349: 385-8.
- Aleksic N, Juneja H, Folsom AR, Ahn C, Boerwinkle E, Chambless W, Wu KK. Prospective study of platelet P1A¹/A² polymorphism, platelet activation, and incidence of coronary heart disease. *Blood* 1998; 92 (suppl 1): 304a-305a.
- Hooper WC, Lally C, Austin H, Benson J, Dilley A, Wenger NK, Whitsett C, Rawlins P, Evatt BL. The relationship between polymorphisms in the endothelial cell nitric oxide synthase gene and the platelet GPIIIa gene with myocardial infarction and venous thromboembolism in African Americans. *Chest* 1999; 116: 880-6.
- Carter AM, Catto AJ, Bamford JM, Grant PJ. Platelet GP IIIa P1A¹ and GP Ib variable number tandem repeat polymorphisms and markers of platelet activation in acute stroke. *Arterioscler Thromb Vasc Biol* 1998; 18: 1124-31.
- Wagner KR, Giles WH, Johnson CJ, Ou C-Y, Bray PF, Goldschmidt-Clermont PJ, Croft JB, Brown VK, Stern BJ, Feeser BR, Buchholz DW, Earley CJ, Macko RF, McCarter RJ, Sloan MA, Stolley PD, Wityk RJ, Wozniak MA, Price TR, Kittner SJ. Platelet glycoprotein receptor IIIa polymorphism P1A² and ischemic stroke risk. *Stroke* 1998; 29: 581-5.
- Corral J, Gonzalez-Conejero R, Rivera J, Iniesta JA, Lozano ML, Vicente V. HPA-1 genotype in arterial thrombosis - role of HPA-1b polymorphism in platelet function. *Blood Coag Fibrinol* 1997; 8: 284-90.
- Carlsson LE, Greinacher A, Spitzer C, Walther R, Kessler C. Polymorphisms of the human platelet antigens HPA-1, HPA-2, HPA-3, and HPA-5 on the platelet receptors for fibrinogen (GPIIb/IIIa), von Willebrand factor (GPIb/IX), and collagen (GPIa/IIa) are not correlated with an increased risk for stroke. *Stroke* 1997; 28: 1392-5.
- Feng D, Lindpaintner K, Larson MG, Rao VS, O'Donnell CJ, Lipinska I, Schmitz C, Sutherland PA, Silbershatz H, D'Agostino RB, Muller JE, Myers RH, Levy D, Tofler GH. Increased platelet aggregability associated with platelet GPIIIa PL^{A2} polymorphism. The Framingham Offspring Study. *Arterioscler Thromb Vasc Biol* 1999; 19: 1142-7.
- Michelsson AD, Furman MI, Goldschmidt-Clermont P, Mascelli MA, Hendrix C, Coleman L, Hamlington J, Barnard MR, Kickler T, Christie DJ, Kundu S, Bray PF. Platelet GPIIIa PL^A polymorphisms display different sensitivities to agonists. *Circulation* 2000; 101: 1013-8.
- Lasne D, Krenn M, Pingault V, Arnaud E, Fiessinger J, Aiach M, Rendu F. Interdonor variability of platelet response to thrombin receptor activation: influence of PL^{A2} polymorphism. *Br J Haematol* 1997; 99: 801-7.
- Meiklejohn DJ, Urbaniak SJ, Greaves M. Platelet glycoprotein IIIa polymorphism HPA 1b (P1A²): no association with platelet fibrinogen binding. *Br J Haematol* 1999; 105: 664-6.
- Vijayan KV, Goldschmidt-Clermont PJ, Roos C, Bray PF. The P1A² polymorphism of integrin β_3 enhances outside-in signaling and adhesive functions. *J Clin Invest* 2000; 105: 793-802.
- Mikkelsson J, Perola M, Laippala P, Savolainen V, Pajarinen J, Lulu Kaisa, Penttilä A, Karhunen PJ. Glycoprotein IIIa P1A polymorphism associates with progression of coronary artery disease and with myocardial infarction in an autopsy series of middle-aged men who died suddenly. *Arterioscler Thromb Vasc Biol* 1999; 19: 2573-8.
- Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin $\alpha_2\beta_1$ density is associated with two silent polymorphisms in the α_2 gene coding sequence. *Blood*. 1997; 89: 1939-43.
- Kritzik M, Savage B, Nugent DJ, Sentoso S, Ruggieri ZM, Kunicki TJ. Nucleotide polymorphisms in the α_2 gene define multiple alleles that are associated with differences in platelet $\alpha_2\beta_1$ density. *Blood* 1998; 92: 2382-8.
- Corral J, Gonzalez-Conejero R, Rivera J, Ortuno F, Aparicio P, Vicente V. Role of the 807 C/T polymorphism of the α_2 gene in platelet GP Ia collagen receptor expression and function. Effect in thromboembolic diseases. *Thromb Haemost* 1999; 81: 951-6.
- Santoso S, Kunicki TJ, Kroll H, Haberbosch W, Gardemann A. Association of the platelet glycoprotein Ia C₄₀₇T gene polymorphism with non-

- fatal myocardial infarction in younger patients. *Blood* 1999; 93: 2449-53.
123. Moshfegh K, Willemin WA, Redondo M, Lämmle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: A case-control study. *Lancet* 1999; 353: 351-4.
 124. Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The α_2 gene coding sequence T807/A873 of the platelet collagen receptor integrin $\alpha_2\beta_1$ might be a genetic risk factor for the development of stroke in younger patients. *Blood* 1999; 93: 3583-6.
 125. Reiner AP, Kumar PN, Schwartz SM, Longstreth Jr, WT, Pearce RM, Rosendaal FR, Psaty BM, Siscovick DS. Genetic variants of platelet glycoprotein receptors and risk of stroke in young women. *Stroke* 2000; 31: 1628-33.
 126. Croft SA, Hampton KK, Sorrell JA, Steeds RP, Channer KS, Samani NJ, Daly ME. The GPIa C807T dimorphism associated with platelet collagen receptor density is not a risk factor for myocardial infarction. *Br J Haematol* 1999; 106: 771-6.
 127. Lopez JA, Ludwig EH, McCarthy BJ. Polymorphism of human platelet glycoprotein Iba results from a variable number of tandem repeats of a 13-amino acid sequence in the mucin-like macroglycopeptide region: structure/function implications. *J Biol Chem* 1992; 267: 10055-61.
 128. Mazzucato M, Pradelles P, de Angelis V, Steffan A, de Marco L. Frequency and functional relevance of genetic threonine¹⁴⁵/methionine¹⁴⁵ dimorphism in platelet glycoprotein Iba in Italian population. *Transfusion* 1996; 36: 891-4.
 129. Li CQ, Garner SF, Davies J, Smethurst PA, Wardell MR, Ouwehand WH. Threonine-145/methionine-145 variants of baculovirus produced recombinant ligand binding domain of GPIba express HPA-2 epitopes and show equal binding of von Willebrand factor. *Blood* 2000; 95: 205-1.
 130. Murata M, Matsubara Y, Kawano K, Zama T, Aoki N, Yoshino H, Watanabe G, Ishikawa K, Ikeda Y. Coronary artery disease and polymorphisms in a receptor mediating shear stress-dependent platelet activation. *Circulation* 1997; 96: 3281-6.
 131. Gonzales-Conejero R, Lozano ML, Rivera J, Corral J, Iniesta JA, Moraleda JM, Vicente V. Polymorphisms of platelet membrane glycoprotein Iba associated with arterial thrombotic disease. *Blood* 1998; 92: 2771-6.
 132. Sonoda A, Murata M, Ito D, Tanahashi N, Ohta A, Tada Y, Takeshita E, Yoshida T, Saito I, Yamamoto M, Ikeda Y, Fukuuchi Y, Watanabe K. Association between platelet glycoprotein Iba genotype and ischemic cerebrovascular disease. *Stroke* 2000; 31: 493-7.
 133. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, McGregor I, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. *Lancet* 1993; 342: 84-6.
 134. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. *Lancet* 1993; 341: 1165-8.
 135. Ridker PM, Hennekens CH, Cerskus A, Stampfer MJ. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. *Circulation* 1994; 90: 2236-40.
 136. Thørgersen AM, Jansson JH, Boman K, Nilsson TK, Weinehall L, Huhtasaari F, Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. *Circulation* 1998; 98: 2241-7.
 137. Lowe GDO, Yarnell JWG, Sweetnam PM, Rumley A, Thomas HF, Elwood PC. Fibrin D-dimer, tissue plasminogen activator, plasminogen activator inhibitor, and the risk of major ischaemic heart disease in the Caerphilly Study. *Thromb Haemost* 1998; 79: 129-33.
 138. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein E, Dilley RB, Loskutoff DJ. Increased type I plasminogen activator inhibitor gene expression in atherosclerotic human arteries. *Proc Natl Acad Sci* 1992; 89: 6998-7002.
 139. Salomaa V, Stinson V, Kark JD, Folsom AR, Davis CE, Wu KK. Association of fibrinolytic parameters with early atherosclerosis: the ARIC study - Atherosclerosis Risk in Communities Study. *Circulation* 1995; 92: 284-90.
 140. Cessari M, Rossi GP. Plasminogen activator inhibitor type 1 in ischemic cardiomyopathy. *Arterioscler Thromb Vasc Biol* 1999; 19: 1378-86.
 141. Chandler WL, Alessi MC, Aillaud MF, Henderson P, Vague P, Juhan-Vague I. Clearance of tissue plasminogen activator (TPA) and TPA-plasminogen activator inhibitor type 1 (PAI-1) complex. Relationship of elevated TPA antigen in patients with high PAI-1 activity levels. *Circulation* 1997; 96: 761-8.
 142. Chandler WL, Stratton JR. Laboratory evaluation of fibrinolysis in patients with a history of myocardial infarction. *Am J Clin Pathol* 1994; 99: 248-52.
 143. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in hepG2 cells. *J Biol Chem* 1993; 268: 10739-45.
 144. Eriksson P, Kallin B, van't Hooft FM, Bavenholm P, Hamsten A. Age-specific increase in basal transcription of the plasminogen activator inhibitor 1 gene is associated with myocardial infarction. *Proc Natl Acad Sci* 1995; 92: 1851-5.
 145. Ossei-Gernung N, Mansfield MW, Stickland MH, Wilson JJ, Grant PJ. Plasminogen activator inhibitor-1 promoter 4G/5G genotype and plasma levels in relation to a history of myocardial infarction in patients characterized by coronary angiography. *Arterioscler Thromb Vasc Biol* 1997; 17: 33-7.
 146. Gardemann A, Lohre J, Katz N, Tillmanns H, Hehrlein FW, Haberbusch W. The 4G/5G genotype of the plasminogen activator inhibitor 1 gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. *Thromb Haemost* 1999; 82: 1121-6.
 147. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambou JP. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the FUSION study. *Thromb Haemost* 1995; 74: 837-41.
 148. Doggen CJM, Bertina RM, Manger Cats V, Reitsma PH, Rosendaal FR. The 4G/5G polymorphism in the plasminogen activator inhibitor 1 gene is not associated with myocardial infarction. *Thromb Haemost* 1999; 82: 115-20.
 149. Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, Manson JE. Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor 1 gene in a large cohort of US men. *Circulation* 1997; 95: 59-62.
 150. Iacoviello L, Burzotta F, Di Castelnuovo A, Zito F, Marchionni R, De Gaetano M, De Stasio MB. The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. *Thromb Haemost* 2000; 82: 1029-30.
 151. Moghadasian MH, McManus BM, Frohlich JJ. Homocysteinemia and coronary artery disease. Clinical evidence and genetic and metabolic background. *Arch Intern Med* 1997; 157: 2299-308.
 152. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. *N Engl J Med* 1998; 338: 1042-5.
 153. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. *JAMA* 1992; 267: 1049-57.
 154. Cattaneo M. Hyperhomocysteinemia, atherosclerosis and thrombosis. *Thromb Haemost* 1999; 81: 165-76.

168. Wilcken DL, Wilcken DL, Wilcken DL. Homocysteine and increased risks of cardiovascular disease. Causal or coincidental? *Arch Intern Med* 2000; 160: 422-34.
169. Wilcken DL, Wilcken DL, Wilcken DL. Plasma homocysteine in the acute and convalescent phases after stroke. *Stroke* 1995; 26: 795-800.
170. Wilcken DL, Wilcken DL, Wilcken DL. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. *J Cardiol* 1996; 77: 759-61.
171. Wilcken DL, Wilcken DL, Wilcken DL. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia associated with vascular disease. The results of a meta-analysis. *Circulation* 1995; 92: 2520-6.
172. Wilcken DL, Wilcken DL, Wilcken DL. The role of lipoprotein(a) in atherosclerosis and thrombosis. *Annu Rev Med* 1996; 47: 423-42.
173. Wilcken DL, Wilcken DL, Wilcken DL. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein concentrations. *J Clin Invest* 1992; 90: 52-60.
174. Wilcken DL, Wilcken DL, Wilcken DL. Lipoprotein Lp(a) excess and coronary heart disease. *Arch Intern Med* 1997; 157: 1170-6.
175. Wilcken DL, Wilcken DL, Wilcken DL. Lipoprotein(a), fibrinolytic activity, and plasminogen activation. *Arteriosclerosis* 1990; 10: 240-5.
176. Wilcken DL, Wilcken DL, Wilcken DL. Anti-fibrinolytic activity of apolipoprotein(a) in vivo: human apolipoprotein(a) transgenic mice are resistant to tissue plasminogen activator-mediated thrombolysis. *Nat Med* 1995; 1: 256-9.
177. Wilcken DL, Wilcken DL, Wilcken DL. Dugas G, Mehran R, Harpel PC, Sharma SK, Marcovina SM, Dube G, Ambrose JA, Fallon JT. Lipoprotein(a) and inflammation in human coronary atheroma: association with the severity of clinical presentation. *J Am Coll Cardiol* 1998; 32: 2035-42.
178. Wilcken DL, Wilcken DL, Wilcken DL. Mamonis HJ, Winder AF, Mikhailidis DP. Lipoprotein(a) and stroke. *J Clin Pathol* 2000; 53: 487-96.
179. Wilcken DL, Wilcken DL, Wilcken DL. Tyrrell J, Cooke T, Reilly M, Colgan M, Moore D, Shanik DG, Bergin C, Feely J. Lipoprotein [Lp(a)] and peripheral vascular disease. *J Intern Med* 1992; 232: 349-52.
180. Wilcken DL, Wilcken DL, Wilcken DL. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis E, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. *JAMA* 1994; 271: 999-1003.
181. Wilcken DL, Wilcken DL, Wilcken DL. Cremer P, Nagel D, Labrot B, Mann H, Mache R, Elster H, Seidel D. Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol, and other risk factors; results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS). *Eur J Clin Invest* 1994; 24: 444-53.
182. Wilcken DL, Wilcken DL, Wilcken DL. Wald NJ, Law M, Watt HC, Wu T, Bailey A, Johnson AM, Craig WY, Lede TB, Haddow JE. Apolipoproteins and ischaemic heart disease: implications for screening. *Lancet* 1994; 43: 75-9.
183. Wilcken DL, Wilcken DL, Wilcken DL. Boston AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger: a prospective study. *JAMA* 1996; 276: 544-8.
184. Wilcken DL, Wilcken DL, Wilcken DL. Wild SH, Fortmann SP, Marcovina SM. A prospective case control study of elevated lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford five-city project participants. *Arterioscler Thromb Vasc Biol* 1997; 17: 239-45.
185. Jauhiainen M, Koskinen P, Ehnholm C, Frick MH, Manttari M, Manninen V, Huttunen JK. Lipoprotein (a) and coronary heart disease risk: a nested case-control study of the Helsinki Heart Study participants. *Atherosclerosis* 1991; 89: 59-67.
186. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. *JAMA* 1993; 270: 2195-9.
187. Cantin B, Gagnon F, Moorjani S, Després JP, Lamarche B, Lupien PJ, Dagenais GR. Is lipoprotein (a) an independent risk factor for ischemic heart disease in men? The Quebec Cardiovascular Study. *J Am Coll Cardiol* 1998; 31: 519-25.
188. Ridker PM. An epidemiologic reassessment of lipoprotein(a) and atherothrombotic risk. *Trends Cardiovasc Med* 1995; 5: 225-9.
189. Maher VMG, Brown G, Marcovina SM, Hillger LA, Zhao X-Q, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). *JAMA* 1995; 274: 1771-4.
190. Kronenberg F, Kronenberg MF, Kiechl S, Trenkwalder E, Santer P, Oberhollenzer F, Egger G, Utermann G, Willeit J. Role of lipoprotein(a) and apolipoprotein(a) phenotype in atherogenesis. Prospective results from the Bruneck Study. *Circulation* 1999; 100: 1154-60.
191. Røsbj O, Berg K. LPA gene: interaction between the apolipoprotein(a) size ('kringle IV' repeat) polymorphism and a pentanucleotide repeat polymorphism influences Lp(a) lipoprotein level. *J Intern Med* 2000; 247: 139-52.
192. Salomaa V, Matei C, Aleksic N, Sansores-Garcia L, Folsom AR, Juneja H, Chambless LE, Wu KK. Soluble thrombomodulin as a predictor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study. *Lancet* 1999; 353: 1729-34.
193. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. *Circulation* 1997; 96: 15-8.
194. Doggen CJM, Kunz G, Rosendaal FR, Lane DA, Vos HL, Stubbs PJ, Manger Cats V, Ireland H. A mutation in the thrombomodulin gene, 127G to A coding for Ala25Thr, and the risk of myocardial infarction in men. *Thromb Haemost* 1998; 78: 743-8.
195. Kunz G, Ireland HA, Stubbs PJ, Kahan M, Coulton GC, Lane DA. Identification and characterization of a thrombomodulin gene mutation coding for an elongated protein with reduced expression in a kindred with myocardial infarction. *Blood* 2000; 95: 569-76.
196. Mansourati J, Da Costa A, Munier S, Mercier B, Tardy B, Ferec C, Isaaz K, Blanc JJ. Prevalence of factor V Leiden in patients with myocardial infarction and normal coronary angiography. *Thromb Haemost* 2000; 83: 822-5.
197. Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on Fibrinogen. *Thromb Haemost* 1995; 73: 151-61.
198. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. *N Engl J Med* 1994; 330: 1041-6.
199. Spielman RS, Ewens WJ. The TDT and other family-based tests for linkage disequilibrium and association. *Am J Hum Genet* 1996; 59: 983-9.

Received July 24, 2000 Accepted after revision September 13, 2000